DGX Nov 2024 140.000 call
| Previous close | 9.30 |
| Open | 9.30 |
| Bid | 6.70 |
| Ask | 7.90 |
| Strike | 140.00 |
| Expiry date | 2024-11-15 |
| Day's range | 9.30 - 9.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 24 |
PR NewswireQuest Diagnostics Completes Acquisition of Select PathAI Diagnostics' Lab Assets from PathAI, Accelerating Adoption of AI and Digital Pathology to Speed Cancer Diagnosis
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition of PathAI Diagnostics from PathAI, with the goal to accelerate the adoption of AI and digital pathology to improve the diagnosis of cancer and other diseases.
ZacksTake the Zacks Approach to Beat the Markets: Robinhood Markets, Victory Capital, NVIDIA in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
- PR Newswire
Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
A blood test could help reduce costs for health plans by reliably identifying patients who might be able to safely forgo chemotherapy after surgery for stage II colorectal cancer, according to a study published today in JAMA Health Forum, a member of the JAMA Network. Researchers from Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company and developer of the Haystack MRD™ tumor-informed ctDNA MRD technology, City of Hope and the Walter and Eliza Hall Institute of Medical Research conducted
